AstraZeneca delivers strong Q2 2025 results with double-digit revenue growth and robust pipeline progress

Overview

AstraZeneca delivered another quarter of strong financial and operational performance in Q2 2025, supported by double-digit revenue growth across Oncology, BioPharmaceuticals, and Rare Disease. The company benefited from sustained global demand, the successful rollout of new therapies, and disciplined cost management. Clinical development advanced significantly, with 12 positive Phase III readouts across key therapy areas, underscoring AstraZeneca’s focus on delivering innovative medicines to patients worldwide.

CEO Pascal Soriot highlighted that the company’s $50bn U.S. investment program, including the largest manufacturing site in its history, is a critical enabler for future growth as AstraZeneca progresses toward its 2030 $80bn revenue ambition.

Q2 2025 vs. Q2 2024:

Total revenue reached $14.46bn (+11% at constant exchange rates (CER) and +12% on a reported basis), driven by robust demand across all therapy areas and geographies.
- Oncology revenue was $6.41bn (+12% at CER), driven by continued global uptake of Tagrisso, Imfinzi, and Enhertu, with particularly strong performance in lung and breast cancer indications. Growth was supported by new indications, favorable market access, and strong ex-U.S. demand.
- BioPharmaceuticals – CVRM (Cardiovascular, Renal & Metabolism) revenue was $3.21bn (+9% at CER), led by Farxiga and Breztri, with expanded adoption in heart failure and chronic kidney disease treatments. Also, a slight margin pressure can be observed due to competitive pricing in certain geographies.
- BioPharmaceuticals – Respiratory & Immunology (R&I) revenue was $2.02bn (+7% at CER), driven by Fasenra and the continued ramp-up of Tezspire, supported by strong demand in the U.S. and Europe.
- Rare Disease (Alexion) revenue was $2.24bn (+15% at CER), a continued growth in Ultomiris and Strensiq, with geographic expansion and new patient starts contributing to robust double-digit performance.
GAAP reported EPS was $1.58 (+31% at CER), reflecting strong operating leverage and lower finance costs.
Core EPS came in at $2.17 (+12% at CER), driven by double-digit top-line growth and disciplined cost control.
Product revenue totaled $14.45bn (+11% at CER), supported by continued growth in flagship medicines including Tagrisso, Imfinzi, Fasenra, and Enhertu.
Gross margin remained strong at 82%, reflecting a favorable product mix with a growing contribution from high-margin oncology therapies.
R&D expenses were $3.45bn (+18% at CER), reflecting accelerated Phase III trials for baxdrostat, gefurulimab, and next-generation oncology therapies, aligned with AstraZeneca’s innovation-led strategy.
SG&A expenses were $3.80bn (+1% at CER), representing 26% of total revenue, as the company continued to invest in global launches while driving productivity improvements.
Operating cash flow remained solid, enabling AstraZeneca to fund both its R&D pipeline and manufacturing expansion initiatives.

AstraZeneca reaffirmed its full-year 2025 guidance at constant exchange rates, supported by strong first-half performance and a robust product portfolio. Total revenue is expected to grow by a high single-digit percentage versus 2024. Core EPS is anticipated to increase by a low double-digit percentage, reflecting operational leverage and cost discipline. Core tax rate is expected to remain between 18-22%. The company expects a neutral FX impact in H2 2025 and continues to generate strong cash flow to support its $50bn U.S. investment program, focusing on next-generation biologics, antibody-drug conjugates (ADCs), rare disease treatments, and manufacturing scale-up. AstraZeneca’s long-term strategy remains centered on accelerating innovation, expanding global access to its medicines, and achieving $80bn in revenue by 2030.

AstraZeneca is currently showing a +3.37% gain on the day. The price has recently crossed above both the 50-day SMA ($71.23) and the 200-day SMA ($70.59), which signals a potential bullish shift after a period of consolidation. The RSI (14) is at 61.59, moving toward the overbought zone but still in healthy territory, suggesting momentum is improving without being overstretched. Key resistance levels are near $75-$77, where previous highs occurred, while support is around $71, aligned with the 50-day SMA. Sustained trading above the 200-day SMA could confirm a trend reversal toward a medium-term bullish outlook.